Harvard Bioscience, Inc. (HBIO)
NASDAQ: HBIO · Real-Time Price · USD
2.160
+0.110 (5.37%)
Nov 20, 2024, 4:00 PM EST - Market closed
Harvard Bioscience Stock Forecast
Stock Price Forecast
There is currently no analyst price target forecast available for Harvard Bioscience.
Analyst Consensus: n/a
Analyst Ratings
There are currently no analyst ratings available for HBIO.
Recommendation Trends
Rating | Jan '23 | Feb '23 | Mar '23 | Apr '23 | May '23 | Jun '23 |
---|---|---|---|---|---|---|
Strong Buy | 0 | 0 | 1 | 2 | 2 | 0 |
Buy | 1 | 1 | 1 | 1 | 1 | 0 |
Hold | 0 | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 1 | 1 | 2 | 3 | 3 | 0 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
Benchmark | Benchmark | Buy Reiterates $7 | Buy | Reiterates | $7 | +224.07% | Jun 22, 2023 |
Benchmark | Benchmark | Strong Buy Maintains $4 → $7 | Strong Buy | Maintains | $4 → $7 | +224.07% | Apr 26, 2023 |
Keybanc | Keybanc | Buy Maintains $5 → $7 | Buy | Maintains | $5 → $7 | +224.07% | Apr 26, 2023 |
Benchmark | Benchmark | Strong Buy Reiterates $4 | Strong Buy | Reiterates | $4 | +85.19% | Mar 10, 2023 |
Keybanc | Keybanc | Buy Maintains $7 → $5 | Buy | Maintains | $7 → $5 | +131.48% | Nov 9, 2022 |
Financial Forecast
Revenue This Year
104.58M
from 112.25M
Decreased by -6.83%
Revenue Next Year
103.79M
from 104.58M
Decreased by -0.76%
EPS This Year
0.11
from -0.08
EPS Next Year
0.15
from 0.11
Increased by 36.36%
Revenue Forecast
Revenue | 2024 | 2025 | 2026 |
---|---|---|---|
High | 122.4M | 109.9M | 117.6M |
Avg | 104.6M | 103.8M | 114.2M |
Low | 90.6M | 96.8M | 109.8M |
Revenue Growth
Revenue Growth | 2024 | 2025 | 2026 |
---|---|---|---|
High | 9.1% | 5.1% | 13.3% |
Avg | -6.8% | -0.8% | 10.1% |
Low | -19.3% | -7.4% | 5.8% |
EPS Forecast
EPS | 2024 | 2025 | 2026 |
---|---|---|---|
High | 0.21 | 0.18 | 0.26 |
Avg | 0.11 | 0.15 | 0.26 |
Low | 0.04 | 0.13 | 0.25 |
EPS Growth
EPS Growth | 2024 | 2025 | 2026 |
---|---|---|---|
High | - | 59.1% | 71.6% |
Avg | - | 36.4% | 66.7% |
Low | - | 13.5% | 60.1% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.